Literature DB >> 11919664

Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride, and fenfluramine on a concurrent choice task.

J D Salamone1, M N Arizzi, M D Sandoval, K M Cervone, J E Aberman.   

Abstract

RATIONALE: Dopamine is important for enabling organisms to overcome work-related response costs. One way of investigating this function has been with concurrent choice procedures using food reinforcement. In the present study, rats were given a choice between pressing a lever for preferred Bioserve pellets, or approaching and consuming a less-preferred laboratory chow that was concurrently available. In previous work with this task, dopamine antagonists and accumbens dopamine depletions decreased lever pressing but increased chow consumption.
OBJECTIVE: The present study assessed three drugs (two dopamine antagonists and one appetite suppressant) using the lever pressing/chow feeding task.
RESULTS: Under baseline conditions, rats pressed the lever at high rates (1,300-1,500 responses) to obtain the preferred food, and little of the laboratory chow was eaten (1-2 g). Selective D1 and D2 antagonists (SKF 83566 and raclopride) reduced fixed ratio 5 lever pressing, but substantially increased chow consumption. In contrast, the serotonergic appetite suppressant fenfluramine reduced both lever pressing and chow consumption. With the dopamine antagonists, lever pressing and chow consumption were inversely correlated across treatments, while these two measures were unrelated in the fenfluramine experiment.
CONCLUSIONS: Dopamine antagonists and accumbens dopamine depletions do not simply reduce appetite. Rats with accumbens dopamine depletions, or rats treated with low doses of selective or non-selective dopamine antagonists, remain directed toward the acquisition and consumption of food. These results demonstrate that fundamental aspects of food reinforcement are left intact after treatment with low doses of dopamine antagonists.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11919664     DOI: 10.1007/s00213-001-0994-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

1.  Phasic nucleus accumbens dopamine release encodes effort- and delay-related costs.

Authors:  Jeremy J Day; Joshua L Jones; R Mark Wightman; Regina M Carelli
Journal:  Biol Psychiatry       Date:  2010-05-10       Impact factor: 13.382

2.  Effects of cortical and striatal dopamine D1 receptor blockade on cued versus noncued behavioral responses.

Authors:  Won Yung Choi; Cecile Morvan Campbell; Peter D Balsam; Jon C Horvitz
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

3.  Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.

Authors:  Samantha E Yohn; Daniela Alberati; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2017-01-12       Impact factor: 4.530

Review 4.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

Review 5.  The nucleus accumbens and Pavlovian reward learning.

Authors:  Jeremy J Day; Regina M Carelli
Journal:  Neuroscientist       Date:  2007-04       Impact factor: 7.519

6.  Forebrain circuitry involved in effort-related choice: Injections of the GABAA agonist muscimol into ventral pallidum alter response allocation in food-seeking behavior.

Authors:  A M Farrar; L Font; M Pereira; S Mingote; J G Bunce; J J Chrobak; J D Salamone
Journal:  Neuroscience       Date:  2008-01-01       Impact factor: 3.590

7.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

8.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

9.  Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.

Authors:  Andrew M Farrar; Mariana Pereira; Francisco Velasco; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

10.  Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.

Authors:  K S Sink; K N Segovia; J Sink; P A Randall; L E Collins; M Correa; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
Journal:  Eur Neuropsychopharmacol       Date:  2009-12-16       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.